Ghasemi Falavarjani Khalil, Iafe Nicholas A, Hubschman Jean-Pierre, Tsui Irena, Sadda Srinivas R, Sarraf David
Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States 2Doheny Eye Institute, University of California Los Angeles, Los Angeles, California, United States 3Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States 4Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States.
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):30-34. doi: 10.1167/iovs.16-20579.
To evaluate the changes in foveal avascular zone (FAZ) area and the retinal capillary density after a single intravitreal anti-VEGF injection for macular edema secondary to diabetic retinopathy or retinal vein occlusion.
In this prospective noncomparative case series, 18 eyes of 15 patients with diabetic macular edema (13 eyes) or macular edema secondary to central retinal vein occlusion (5 eyes) were included. Optical coherence tomography angiography (OCTA) images were obtained, and retinal capillary vessel density and FAZ area were measured in the foveal and parafoveal regions at the level of the superficial (SCP) and deep retinal capillary plexus (DCP) before and at the first visit after intravitreal injection.
The mean interval between baseline and follow up OCTA was 32.5 ± 9.4 (range, 21-50) days. Foveal and parafoveal vessel density in the SCP and DCP were not significantly different before and after intravitreal injection (all P > 0.1), nor was FAZ area (P = 0.48 and P = 0.42, respectively). No significant difference was found between eyes with diabetic macular edema and those with retinal vein occlusion with respect to the mean change of vessel density and FAZ area (all P > 0.05).
In this pilot study, retinal capillary density and FAZ area remained statistically unchanged in the short-term after a single intravitreal injection of an anti-VEGF agent.
评估单次玻璃体腔内注射抗血管内皮生长因子（VEGF）药物治疗糖尿病性视网膜病变或视网膜静脉阻塞继发黄斑水肿后，黄斑无血管区（FAZ）面积及视网膜毛细血管密度的变化。
在这项前瞻性非对照病例系列研究中，纳入了15例糖尿病性黄斑水肿患者的18只眼（其中13只眼）以及视网膜中央静脉阻塞继发黄斑水肿患者的5只眼。获取光学相干断层扫描血管造影（OCTA）图像，并在玻璃体腔内注射前及注射后首次就诊时，测量黄斑区和黄斑旁区域浅表视网膜毛细血管丛（SCP）和深层视网膜毛细血管丛（DCP）水平的视网膜毛细血管密度及FAZ面积。
基线OCTA与随访OCTA之间的平均间隔时间为32.5±9.4（范围21 - 50）天。玻璃体腔内注射前后，SCP和DCP中黄斑区及黄斑旁血管密度无显著差异（所有P>0.1），FAZ面积也无显著差异（分别为P = 0.48和P = 0.42）。糖尿病性黄斑水肿眼与视网膜静脉阻塞眼在血管密度和FAZ面积的平均变化方面无显著差异（所有P>0.05）。
在这项初步研究中，单次玻璃体腔内注射抗VEGF药物后短期内，视网膜毛细血管密度和FAZ面积在统计学上保持不变。
